Posterior staphyloma risk and anatomy in Europeans with high myopia
Official title: Risk of Posterior Staphyloma in Highly Myopic Europeans : From Epidemiology to Anatomy.
Run by Assistance Publique - Hôpitaux de Paris · NCT06949579 · Data updated 2026-11-12
This project will try to find genetic differences and blood markers linked to posterior staphyloma in adults of European descent who have high myopia.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 200 (estimated) |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris) |
| Status | Recruiting |
| Started | February 12, 2026 |
| Main results expected | December 2027 |
| Study ends | December 2027 |
| Registry record updated | August 7, 2026 |
| Trial ID | NCT06949579 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) of European ancestry with high myopia (axial length ≥26.0 mm or ≤ −6.0 diopters), good-quality retinal imaging, the ability to consent, and social security coverage are ideal candidates.
✕Probably not a fit
Patients with systemic or ocular conditions affecting the posterior segment (for example diabetes, systemic inflammatory disease, retinitis pigmentosa, syndromic or genetically-associated myopia) are excluded and are unlikely to benefit from this genetic-focused project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multi-center, cross-sectional project will enroll 600 European adults with high myopia across three centers in France, Spain, and the Netherlands and collect blood for DNA and standardized retinal imaging. Participants will be divided into 300 with posterior staphyloma and 300 without, and a genome-wide association study (GWAS) will compare SNP frequencies between the two groups while adjusting for age, sex, axial length, and genetic ancestry. Significant loci will undergo functional annotation and pathway enrichment analyses, and exploratory analyses will relate genetic findings to retinal imaging phenotypes. All clinical and genetic data will be entered into a centralized Castor database under a harmonized protocol to ensure uniform phenotyping.
Why it matters
Potential benefit: If successful, the findings could help identify people at higher genetic risk for posterior staphyloma and point to biological pathways that may enable earlier monitoring or guide future treatments.
How similar studies have gone: Large GWAS have successfully identified genetic risk factors for general myopia, but applying GWAS specifically to posterior staphyloma in well-phenotyped European cohorts is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults with high myopia (axial length ≥ 26.00 mm or degree of myopia of at least -6 diopters), with and without posterior staphyloma * Adults aged 18 years or over * Patient with high myopia (axial length ≥ 26.00 mm or degree of myopia of at least -6 diopters), with good quality retinal imaging * Patient who has signed a consent form to participate in the study * Patient who is a beneficiary of a social security scheme or who is entitled to it Exclusion Criteria: * Any systemic or ocular pathologies with an impact on the posterior segment of the eye * Patient with a systemic pathology likely to affect the posterior segment of the eye: * Diabetes * Systemic inflammatory disease: sarcoidosis, rheumatoid arthritis, systemic lupus erythematosus, Horton's disease * Patients with retinitis pigmentosa * Patients with syndromic myopia * Patients with myopia associated with a genetic disease such as hereditary vitreoretinopathy * Patients under guardianship, curatorship or legal protection, as well as pregnant or breastfeeding women (article L1121-5 of the CSP).
Where it's running
-
Cochin Hospital
Paris, France Recruiting
Study contacts
- Principal investigator: Francine BEHAR-COHEN, MD,PhD — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Francine Behar-Cohen, MD, PhD
- Email: francine.cohen@aphp.fr
- Phone: 06 60 97 44 19
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-powered fundus platform to detect posterior scleral staphyloma in high myopia
This project will test an AI platform that uses widefield photos, B-scan, and OCT to find posterior scleral staphyloma in people with high myopia and cataract.
-
Capsular tension ring to improve intraocular lens stability in people with high myopia and cataracts
This test will see if placing a capsular tension ring in one eye during cataract surgery helps the artificial lens stay centered and gives better vision for people with high myopia, by comparing the treated eye to the other eye without the ring.
-
Using artificial intelligence to improve cataract surgery outcomes for patients with high myopia
This study is testing a new artificial intelligence tool to see if it can help improve cataract surgery results for patients with severe nearsightedness by providing better lens calculations.
-
Observing long-term changes in high myopia patients
This study is tracking changes in eye health and vision over four years in college students with high myopia to see if they can find clues to help manage the condition better.
-
Using SMILE to correct high myopia
This study is testing if a new eye surgery called SMILE can help people with very poor eyesight (high myopia) see better and recover quickly.
-
Evaluating long-term visual outcomes after cataract surgery in high myopia patients
This study looks at how cataract surgery affects vision over time in people with severe nearsightedness compared to those with regular age-related cataracts.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.